AstraZeneca leaps as Soriot strategy starts to pay off

26 July 2018

The strategy pursued by Pascal Soriot since he took over as AstraZeneca (LSE: AZN) chief executive in 2012 – of investing massively in R&D in the hope of replacing revenues lost through expiring patents – has arguably been one of the bravest in pharma.

There has been no shortage of criticism, too, particularly after a bad read-out of results from the MYSTIC trial of the immuno-oncology (IO) drug Imfinzi (durvalumab) last summer – with the Anglo-Swedish company losing £10 billion ($13.2 billion) in market value in a day and the Frenchman’s strategy and salary subsequently being questioned.

The latest financial results – which led to AstraZeneca’s share price jumping by 2.5% in five hours of trading – are evidence that perhaps that investment is starting to bear fruit, with figures looking healthy despite the loss of exclusivity of Crestor (rosuvastatin calcium) bringing sales in the cardiovascular drug down by 40% compared to the second quarter of 2017.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK